Impact Of Dose Intensity Of Capox And Mfolfox6 On Survival Of Stage Iii Colorectal Cancer Patients: A Retrospective Analysis At Two Canadian Institutions Between 2006-2013.

e14664 Background: Standard of care in the treatment of stage III colorectal cancer (CRC) involves 6 months of adjuvant combination chemotherapy with 5-FU and oxaliplatin. Despite lack of true comparative study, 2 regimens FOLFOX (MOSAIC trial) and CAPOX (XELOXA trial) are believed to be similar in their efficacy and tolerability. However, the latter has been disputed as real-life data presented from Canada has shown CAPOX to be more toxic, leading to more frequent rate of reduction in its dose intensity. Consequently, its impact on clinical outcomes has been brought to question. Methods: A retrospective data review was conducted by Segal Cancer Centre (SCC) Quebec, and Tom Baker Cancer Centre (TBCC) Alberta, on patients with stage III CRC between 2006-2013. Patients were treated with either CAPOX or mFOLFOX6 as per Canadian treatment guidelines. Primary endpoints were dose intensity and toxicity with secondary endpoints disease free survival (DFS) and overall survival (OS). Results: 180 patients (80 SCC,...